Avelumab

Generic Name
Avelumab
Brand Names
Bavencio
Drug Type
Biotech
Chemical Formula
-
CAS Number
1537032-82-8
Unique Ingredient Identifier
KXG2PJ551I
Background

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.

Indication

Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.

It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).

Associated Conditions
Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
Associated Therapies
First Line Chemotherapy, Maintenance therapy

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

First Posted Date
2018-01-05
Last Posted Date
2024-10-10
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
24
Registration Number
NCT03391479
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment

Phase 2
Completed
Conditions
Interventions
First Posted Date
2018-01-03
Last Posted Date
2021-03-17
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
30
Registration Number
NCT03389126
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Survival Prolongation by Rationale Innovative Genomics

First Posted Date
2017-12-29
Last Posted Date
2023-12-18
Lead Sponsor
Worldwide Innovative Network Association
Target Recruit Count
15
Registration Number
NCT03386929
Locations
🇺🇸

Avera Cancer Center, Sioux Falls, South Dakota, United States

🇱🇺

Centre Hospitalier Luxembourg, Luxembourg, Luxembourg

🇮🇱

Chaim Sheba Medical Center, Ramat Gan, Israel

and more 2 locations

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-11-24
Last Posted Date
2022-02-25
Lead Sponsor
Johannes Gutenberg University Mainz
Target Recruit Count
60
Registration Number
NCT03352934
Locations
🇩🇪

Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg, Heidelberg, Germany

🇩🇪

Poliklinik für Innere Medizin I Universitätsklinikum Halle, Halle (Saale), Germany

🇩🇪

Schwerpunkt Endokrinologie und Stoffwechselerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany

and more 1 locations

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

First Posted Date
2017-11-14
Last Posted Date
2022-01-04
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
13
Registration Number
NCT03341806
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2017-11-14
Last Posted Date
2018-05-21
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
40
Registration Number
NCT03341845
Locations
🇳🇱

Antoni van Leeuwenhoek, Amsterdam, Netherlands

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2017-10-27
Last Posted Date
2022-05-03
Lead Sponsor
University Hospital, Bordeaux
Target Recruit Count
65
Registration Number
NCT03324282
Locations
🇫🇷

Hôpital Saint-Louis, AP-HP, Paris, France

🇫🇷

Hôpital Européen Georges-Pompidou, AP-HP, Paris, France

🇫🇷

CHU de Besançon, Besançon, France

and more 10 locations
© Copyright 2024. All Rights Reserved by MedPath